Spero Therapeutics (SPRO) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Spero Therapeutics (SPRO) over the last 5 years, with Q3 2025 value amounting to -$0.13.
- Spero Therapeutics' EPS (Weighted Average and Diluted) rose 5937.5% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.79, marking a year-over-year decrease of 108750.0%. This contributed to the annual value of -$1.27 for FY2024, which is 39533.96% down from last year.
- As of Q3 2025, Spero Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.13, which was up 5937.5% from -$0.03 recorded in Q2 2025.
- Over the past 5 years, Spero Therapeutics' EPS (Weighted Average and Diluted) peaked at $0.97 during Q4 2023, and registered a low of -$1.01 during Q1 2022.
- In the last 5 years, Spero Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.29 in 2024 and averaged -$0.28.
- As far as peak fluctuations go, Spero Therapeutics' EPS (Weighted Average and Diluted) surged by 17948.92% in 2022, and later tumbled by 43333.33% in 2024.
- Over the past 5 years, Spero Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.92 in 2021, then soared by 179.49% to $0.73 in 2022, then skyrocketed by 32.64% to $0.97 in 2023, then crashed by 138.93% to -$0.38 in 2024, then skyrocketed by 65.58% to -$0.13 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.13 for Q3 2025, versus -$0.03 for Q2 2025 and -$0.25 for Q1 2025.